Celldex Therapeutics, Inc. has rallied over 70% off April 2025 lows, driven by optimism for lead candidate barzolvolimab in ...

Pre-clinical data supports ECRIs' broad-spectrum attack on the IgE axis, distinct from conventional anti-IgE therapies, ...

Redefining Allergy Treatment with New Class of Trifunctional ECRIs designed to deliver powerful efficacy, rapid relief and complete control of ...

The allergic rhino-conjunctivitis market is experiencing steady growth, driven by the rising prevalence of allergic ...

Novartis (NYSE:NVS) is one of the best growth stocks to buy now. On September 30, Novartis announced the US FDA approval of ...

When my kids were little, I shelled out a pile of hard-earned dollars to make matching Popeye the Sailor Man costumes. I spent entire evenings determined to make them authentic to the muscular guy ...

US stocks jumped Monday in a broad rebound, bouncing back from Friday's rout after President Trump played down the escalating ...